News & Insights

Oxford Technology & Innovations EIS Fund (OTIF) subscribes to exascale compute company Salience Labs’ $11.5m Seed funding round

  • Salience Labs Ltd, a spinout of the Universities of Oxford and Münster, raises $11.5m to develop ultra-high-speed photonics chip and accelerate exponential gains in AI
  • The round was led by Oxford Science Enterprises and Cambridge Innovation Capital with participation from Yew Lin Goh of Leedon Park Ventures, Arm-backed Deeptech Labs and former CEO of Dialog Semiconductor Jalal Bagherli
  • Salience Lab’s technology solves the widening market gap between AI demand for ultra-fast processing and Semiconductor industry supply
Read post

Oxford Technology & Innovations EIS Fund (OTIF) and co-investors subscribe to Oxford University spinout company Orthox Ltd.’s £9.2m Series A funding round

  • Orthox has announced the completion of a further £3.2m to close its £9.2m Series A financing round.
  • Orthox is a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries.
  • The financing will support further clinical trials of its lead product, FibroFix™, at Southmead Hospital Bristol, UK and in Budapest, Hungary.
Read post

Oxford Technology & Innovations EIS Fund (OTIF) and co-investors participate in Cambridge company Biofidelity Ltd’s £17.3m Series A+ financing

  • Biofidelity has closed a £17.3m Series A+ funding round led by led by Octopus Ventures and SBI Investment Co Ltd.
  • The capital will be used to commercialise Biofidelity’s ASPYRE technology, a high sensitivity molecular diagnostic platform and the first assay for high sensitivity diagnosis of non-small-cell-lung-cancer. This is will include launch in North America.
  • The funding will also be used to expand and validate Biofidelity’s technology platform on other key oncology applications where access to high sensitivity precision diagnostics is key to improving outcomes.
Read post

Oxford Technology & Innovations EIS Fund (OTIF) and co-investors participate in ONI’s $75m Series B financing

  • ONI has closed a $75m Series B financing led by US investors ARCH Venture Partners and Casdin Capital.
  • ONI is a pioneer in observing single molecules in living cells. The Company’s first product, the Nanoimager, is the world’s first desktop, super-resolution, single-molecule imaging platform capable of visualising and tracking individual molecules in complex systems such as nanoparticles, living cells and tissue with 20nm resolution.
  • The Series B funds will be used to build a product portfolio that harnesses the Company’s innovative technology to unlock new possibilities in therapeutic and diagnostic development, as well as basic life sciences research.
Read post